Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 26, 2011

Kuros Biosurgery Regains Trauma and Spinal Repair Candidates from Baxter

  • Biomaterials firm Kuros Biosurgery regained its rights to a number of clinical-stage trauma and spinal repair candidates previously licensed to Baxter. The two firms will, however, continue to partner on development of a chronic wounds therapy candidate, KUR-211, which is currently in Phase II development in Europe in patients with diabetic foot ulcers.

    The products regained by Kuros include KUR-111, KUR-113, and KUR-115. KUR-111 is an autograft replacement candidate that combines a fibrin matrix, variant parathyroid hormone (PTH), and hydroxyapatite/calcium phosphate granules. The product has demonstrated noninferiority to autograft in a Phase II tibial plateau fractures study involving 183 patients. KUR-113 comprises fibrin matrix and a variant PTH, and is designed to promote bone formation and accelerate fracture repair. Data reported separately today from a Phase II study in open tibial shaft fractures showed that in comparison with standard of care, KUR-113 significantly increased the proportion of patients who were healed at six months after surgery. Preclinical-stage product, KUR-115, is being prepared for clinical studies in spinal fusion patients.

    The wound care product KUR-211, which Baxter and Kuros are continuing to co-develop, is a combination product in which an engineered variant of platelet-derived growth factor is applied to the wound in combination with a fibrin matrix. A large European Phase IIb clinical trial is evaluating the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcers. Kuros has previously completed two clinical studies with KUR-211 in chronic wounds: one Phase I/II dose-finding study in venous ulcer patients, and an exploratory study in diabetic ulcer patients.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »